Students of tuberculosis have been interested in the immune response to M. tuberculosis since the modern understanding of the clinical disease. For decades the skin test response to tuberculin (TST) was the primary tool clinicians have had for study. With the development of Interferon Gamma Release Assays (IGRA) the recurrent question has been which is better, the TST or an IGRA. Hundreds of papers have been written on this matter and numerous guidelines have been issued. This conference will provide a solid framework within which to assess the rapidly moving field as well as provide a basis for making clinical decisions.
This meeting will present basic and developing information which will be of interest to academic physicians, practicing physicians such as those who practice infectious disease, pulmonary medicine, pediatrics as well as public health physicians, dermatologists, Rheumatologists, Gastroenterologists and epidemiologists.
At the conclusion of this course, participants should be able to:
Based on a review of recently published literature, faculty comments, and audience feedback from recent CME/CE programming, the organizing faculty has identified ongoing educational needs for physicians and related healthcare professionals involved in the management of TB.
Educational gaps have been identified in the need to understand 1) the dynamics of TB infection, 2) the interactions between immune modifiers and progression of TB infection, 3) the use of IGRAs in HIV infected, in the face of immune modifiers, in HCW, 4) the use of IGRAs in public health situations such as contact studies and pediatrics settings 5) new treatment of LTBI and 6) the eradication of TB by 2050.
Grant support provided by